What is your preferred adjuvant systemic treatment for resected stage IV melanoma with a BRAF mutation?
Based on available results from the IMMUNED trial, which evaluated the role of adjuvant nivolumab/ipilimumab or nivolumab monotherapy vs placebo in resected stage IV melanoma, would you still consider BRAF/MEK targeted therapy as an option?
Community PollStarted
What is your preferred adjuvant systemic treatment for resected stage IV melanoma with a BRAF mutation?
29 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on
I agree with @Dr. First Last and prefer single-agent anti-PD1 therapy for adjuvant setting as well, given better tolerance and preserved QoL for most patients. I use targeted therapy in contraindications to ICI therapy, or prior exposure to ICI, and now with resected NED setting.
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · The Ohio State University Comprehensive Cancer Center
Answered on
Unless there is a contraindication to immunotherapy, I would recommend the standard of care single agent PD1 inhibitor. If there is a contraindication, BRAF inhibitors are the drugs of choice.
Join for free or sign in to see the full answer